Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from MaxCyte ( (MXCT) ) is now available.
On August 11, 2025, Ali Soleymannezhad’s employment as Chief Commercial Officer of MaxCyte, Inc. ended. In accordance with his Severance Agreement, he will receive his base salary and healthcare contributions for nine months, contingent upon compliance with the agreement’s terms.
The most recent analyst rating on (MXCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.
Spark’s Take on MXCT Stock
According to Spark, TipRanks’ AI Analyst, MXCT is a Neutral.
MaxCyte’s financial challenges and valuation concerns weigh heavily on the stock’s score. However, strong shareholder support, strategic plans, and a solid cash position provide a basis for potential recovery, especially if operational efficiencies improve and macroeconomic conditions stabilize.
To see Spark’s full report on MXCT stock, click here.
More about MaxCyte
Average Trading Volume: 866,173
Technical Sentiment Signal: Sell
Current Market Cap: $147.1M
See more data about MXCT stock on TipRanks’ Stock Analysis page.